RINX
USPTO CORRECTION PROCESSED BY IB
05/14/2024
Back to search
Official data from USPTO
NRAVEL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NRAVEL
ST13
US500000079340988Class
5, 42, 44
Filing
79340988
Registration
7232511
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
05/14/2024
Trademark type
Word
Nice classes
5, 42, 44
Filing date
08/23/2021
Registration date
12/05/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/05/2023
Last transaction
03/14/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
27
Owner location
DE
Examiner
ZARICK, DIANA G
Law office
N80
Current location
TMO LAW OFFICE 126
Holders and representatives
Holders
Indivumed GmbH
Representatives
R. Glenn Schroeder Schroeder Law PC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparationsin particular medicines for human beings and animalsfor the treatment of cancermetabolic diseasescardiovascular diseasesinflammatory diseasesdiseases of the immune system; human and animal sample materialsfor medical purposestumor tissues and tissue grafts samplesbloodserumplasmaurinestoolsallograft or xenograft tissue preparationstissue cutsblood plasmablood serumascites being bodily fluidscerebrospinal fluidhuman and animal urine and human and animal stool; test kits of human and animal sample materialscomprising diagnostic reagents for medical purposeshuman and animal allograft and xenograft tissuetissue cuts being biological tissue grafts and biological tissue culturesblood plasmablood serumascites being bodily fluidscerebrospinal fluidhuman and animal urine and human and animal stool; diagnostic preparationsin particular made by using molecular biologicalmolecular geneticgenetic engineeringimmunological and biotechnical methods for medical use; therapeutic preparationsin particular made by using molecular biologicalmolecular geneticgenetic engineeringimmunological and biotechnical methodsfor medical use for the treatment of cancer; biological material collectionsbiological tissue cultures for medical purposes; cancer material collectionsbiological tissue being resected and biopsy tumor and adjacent non-tumor tissue from the human body including epithelialconnectivemuscularnervous tissuesbloodserumplasmaurinestools for medical purposes; medical sample collectionsbiological tissue cultures for medical purposes; biological sample collections from the human bodyepithelialconnectivemuscularnervous tissuesbloodserumplasmaurinestools for medical purposes; biopsy material collectionsbiological tissue in the nature of bloodbiological tissue grafts and biological tissue cultures for medical purposes; all the afore-mentioned in particular with regard to the field of oncology
Class 42
Collection of clinical data for medical research and development of therapeutics and diagnostics; collecting geneticmedicalbiomedicalbiologicchemical and biochemical data and informationin particular information generated through the use of imaging techniquesthe use of liquid biopsy methodsthe use of histopathological analysis and proceduresthe use of genetic analysis and the use of genomicsproteomicstranscriptomicsmetabolomicslipidomics and/or glycomics studies and analysis for medical research; scientific and technological servicesresearchdesign and development of new technology for others in the field of cancermetabolic diseasescardiovascular diseasesinflammatory diseasesdiseases of the immune system; industrial analysis and research services in the field of cancermetabolic diseasescardiovascular diseasesinflammatory diseasesdiseases of the immune system; design and development of computer hardware and softwarein particular computer programs; scientific research for medical purposesmolecular biologicalimmunological and histological laboratory servicesin particular research and development in the field of human medical and veterinary medical diagnostics and therapy; typing of tissue and tissue samplesin particular using molecular biologicalimmunologicalgenetic engineering and histological methods for research purposes; preparation of human and animal biospecimen for research purposes; providing information and data relating to medical and veterinary research on human and animal biospecimenin particular genomicepigenomicproteomicphosphoproteomicRNAtranscriptomiclipidomic and metabolomic data; medical laboratory services for medical research purposesother than for diagnostic or treatment purposestyping of tissue and tissue samplesin particular using molecular biologicalimmunologicalgenetic engineering and histological methods; database design and development; software as a service (SAAS) serviceshosting software for use by others for use as a database; installationmaintenance and updating of database software; providing scientific research information and results from an online searchable database; programming of computer software for databases; scientific and laboratory analysis using bioinformatics and computational biology in the field of oncology; all the afore-mentioned in particular with regard to the field of oncology
Class 44
Medical analyses in connection with the treatment of individuals including medical analysis of X-rays and blood samplesmedical testing for diagnostic and treatment purposes; medical clinic services; pharmaceutical advisory services; medical analysis services using bioinformatics and computational biologyfor patient diagnostic and treatment purposes; providing supporting services and advice to hospitals and other medical care centrescollecting and stabilizing of human and animal biospecimensproviding advice related theretothe collection of related clinical data for patient diagnostic and treatment purposes; all the afore-mentioned in particular with regard to the field of oncology
Publications
History of USPTO decisions and trademark events.
47 publications found
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
04/23/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/08/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/14/2024
FIMP
FINAL DISPOSITION PROCESSED
03/14/2024
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
03/14/2024
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
03/13/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/05/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/05/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
12/05/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/12/2023
RINX
USPTO CORRECTION PROCESSED BY IB
10/30/2023
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
10/30/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/25/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/25/2023
GPNX
NOTIFICATION PROCESSED BY IB
10/24/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/19/2023
PUBO
PUBLISHED FOR OPPOSITION
09/19/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/30/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/30/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/30/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/11/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
08/11/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/11/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
08/11/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/25/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/24/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/24/2023
RFNP
REFUSAL PROCESSED BY IB
02/28/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/26/2023
GNRT
NON-FINAL ACTION E-MAILED
01/26/2023
CNRT
NON-FINAL ACTION WRITTEN
01/26/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/21/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/21/2022
CRSN
CORRECTION SENT TO IB
12/07/2022
CRCR
CORRECTION CREATED FOR IB
12/07/2022
RFNP
REFUSAL PROCESSED BY IB
07/13/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/23/2022
RFRR
REFUSAL PROCESSED BY MPU
06/22/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/28/2022
CNRT
NON-FINAL ACTION WRITTEN
05/27/2022
MAFR
APPLICATION FILING RECEIPT MAILED
05/27/2022
DOCK
ASSIGNED TO EXAMINER
05/25/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/23/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/19/2022
Continuous trademark protection
Get notified about every new filing that threatens NRAVEL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.